{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:32:46Z","timestamp":1777955566844,"version":"3.51.4"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die St\u00e4ndige Impfkommission (STIKO) hat im Oktober 2024 ihre Empfehlung zur saisonalen Influenza-Impfung f\u00fcr Personen ab 60 Jahren angepasst. Aufgrund neuer Studiendaten wird der MF59-adjuvantierte Influenza-Impfstoff nun neben dem Hochdosis-Impfstoff gleichwertig empfohlen: Es zeigte sich eine \u00dcberlegenheit des MF59-adjuvantierten Impfstoffs hinsichtlich der Effektivit\u00e4t im Vergleich zu nicht-adjuvantierten Standardimpfstoffen bei \u00e4lteren Erwachsenen. Die Immunantwort auf den adjuvantierten Impfstoff ist mitunter breiter und st\u00e4rker als gegen Standardimpfstoff. Der MF59-adjuvantierte Impfstoff wies ein \u00e4hnliches Sicherheitsprofil auf wie der Hochdosis-Impfstoff, beide zeigten im Vergleich zum Standardimpfstoff leicht erh\u00f6hte lokale und systemische Reaktogenit\u00e4t. Die STIKO geht davon aus, dass die Empfehlung beider Impfstoffe Akzeptanz und Impfbereitschaft in der Zielpopulation steigern k\u00f6nnte.<\/jats:p>","DOI":"10.1055\/a-2812-2784","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:52Z","timestamp":1777934632000},"page":"501-508","source":"Crossref","is-referenced-by-count":0,"title":["STIKO-Empfehlung: MF59-adjuvantierter Influenza-Impfstoff f\u00fcr Menschen \u2265 60 Jahre"],"prefix":"10.1055","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-2764","authenticated-orcid":false,"given":"Martina","family":"Prelog","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg: Universitatsklinikum Wurzburg, GERMANY","place":["Wuerzburg"],"department":["P\u00e4diatrische Rheumatologie\/Spezielle Immunologie"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"G\u00e4rtner","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum des Saarlandes, Institut f\u00fcr Medizinische Mikrobiologie und Hygiene, Homburg\/Saar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Leischker","sequence":"additional","affiliation":[{"name":"Brohtalklinik St. Josef, Burgbrohl"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Rieger","sequence":"additional","affiliation":[{"name":"H\u00e4matologie Onkologie Germering, Landsberger Stra\u00dfe 27, Germering"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf-Peter","family":"Vonberg","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Institut f\u00fcr Medizinische Mikrobiologie und Krankenhaushygiene, Hannover"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tino F.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Klinikum W\u00fcrzburg Mitte, Standort Juliusspital, Institut f\u00fcr Labormedizin und Impfzentrum, W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/12901","article-title":"Beschluss und Wissenschaftliche Begr\u00fcndung zur Anpassung der STIKO-Empfehlung einer Standardimpfung f\u00fcr Personen \u2265\u200960 Jahre zum Schutz vor Erkrankungen durch saisonale Influenzaviren","author":"J Schlaberg","year":"2024","journal-title":"Epidemiologisches Bulletin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13054-019-2539-x","article-title":"Influenza virus-related critical illness: pathophysiology and epidemiology","volume":"23","author":"AC Kalil","year":"2019","journal-title":"Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/7655","article-title":"Beschluss und Wissenschaftliche Begr\u00fcndung der St\u00e4ndigen Impfkommission (STIKO) f\u00fcr die Aktualisierung der Influenza-Impfempfehlung f\u00fcr Personen im Alter von \u2265 60 Jahren","author":"K Michaelis","year":"2020"},{"issue":"S 1","key":"ref6","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1016\/j.vaccine.2020.09.048","article-title":"The disease burden of influenza beyond respiratory illness","volume":"39","author":"AE Macias","year":"2021","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019636","article-title":"Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"10","author":"SH Yedlapati","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1324677","article-title":"Influenza vaccine effect on risk of stroke occurrence: a systematic review and meta-analysis","volume":"14","author":"JA Zahhar","year":"2023","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70071","article-title":"Neurologic Complications of Influenza and Potential Protective Vaccine Effects","volume":"19","author":"AR Falsey","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13314","article-title":"Senescent cells and the incidence of age-related diseases","volume":"20","author":"I Katzir","year":"2021","journal-title":"Aging Cell"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101422","article-title":"Immunosenescence and inflammaging in the aging process: age-related diseases or longevity?","volume":"71","author":"A Santoro","year":"2021","journal-title":"Ageing Res Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2014.3085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"AK Simon","year":"2015","journal-title":"Proc Biol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1876326X01206010064","article-title":"Balancing the Efficacy and Safety of Vaccines in the Elderly","volume":"6","author":"IJ Amanna","year":"2012","journal-title":"Open Longev Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae203","article-title":"Number of Influenza Risk Factors Informs an Adult\u2019s Increased Potential of Severe Influenza Outcomes: A Multiseason Cohort Study From 2015 to 2020","volume":"11","author":"I McGovern","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00103-019-02921-1","article-title":"Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen","volume":"62","author":"R Wagner","year":"2019","journal-title":"Bundesgesundheitsblatt \u2013 Gesundheitsforschung \u2013 Gesundheitsschutz"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"T Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-023-00608-y","article-title":"Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions","volume":"8","author":"KJ Fisher","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"S Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11081391","article-title":"Advances in Adjuvanted Influenza Vaccines","volume":"11","author":"S Shichinohe","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13286","article-title":"Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials","volume":"18","author":"J Youhanna","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/s41467-023-37162-z","article-title":"Commercial influenza vaccines vary in HA-complex structure and in induction of cross-reactive HA antibodies","volume":"14","author":"ML Myers","year":"2023","journal-title":"Nat Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-021-00289-5","article-title":"Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults","volume":"6","author":"APY Li","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.coviro.2013.05.001","article-title":"Role of T cell immunity in recovery from influenza virus infection","volume":"3","author":"J Sun","year":"2013","journal-title":"Curr Opin Virol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2900\/072225","volume-title":"Systematic review update on the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over","author":"(ECDC) ECfDPaC","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijid.2022.10.041","article-title":"Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults","volume":"125","author":"A Domnich","year":"2022","journal-title":"Int J Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107160","article-title":"Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017\u20132020 influenza seasons","volume":"146","author":"I McGovern","year":"2024","journal-title":"Int J Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae375","article-title":"Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022\u20132023 Influenza Season Among Adults >\/=65 Years of Age","author":"JH Ku","year":"2024","journal-title":"Clin Infect Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101518","article-title":"Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024\u20132025 season: a target trial emulation study based on registry data","volume":"60","author":"K Faksova","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31266","article-title":"Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial","volume":"4","author":"KE Schmader","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3109\/00365548.2011.580777","article-title":"Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy","volume":"43","author":"TF Tsai","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1016\/j.vaccine.2009.03.091","article-title":"Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness","volume":"27","author":"CJ Phillips","year":"2009","journal-title":"Vaccine"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejim.2009.12.001","article-title":"Vaccination, squalene and anti-squalene antibodies: facts or fiction?","volume":"21","author":"G Lippi","year":"2010","journal-title":"Eur J Intern Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.vaccine.2022.11.046","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial","volume":"41","author":"K Cannon","year":"2023","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.5646","article-title":"Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults >\/=50 Years: A Randomized Clinical Trial","author":"AK Rudman Spergel","year":"2025","journal-title":"JAMA"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2812-2784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:01Z","timestamp":1777934641000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2812-2784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2812-2784","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}